JNJ

228.72

+0.02%↑

UNH

369.71

+0.45%↑

TMO

471.41

-0.54%↓

ISRG

460.06

+1.73%↑

ABT

89.46

-1.05%↓

JNJ

228.72

+0.02%↑

UNH

369.71

+0.45%↑

TMO

471.41

-0.54%↓

ISRG

460.06

+1.73%↑

ABT

89.46

-1.05%↓

JNJ

228.72

+0.02%↑

UNH

369.71

+0.45%↑

TMO

471.41

-0.54%↓

ISRG

460.06

+1.73%↑

ABT

89.46

-1.05%↓

JNJ

228.72

+0.02%↑

UNH

369.71

+0.45%↑

TMO

471.41

-0.54%↓

ISRG

460.06

+1.73%↑

ABT

89.46

-1.05%↓

JNJ

228.72

+0.02%↑

UNH

369.71

+0.45%↑

TMO

471.41

-0.54%↓

ISRG

460.06

+1.73%↑

ABT

89.46

-1.05%↓

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Avatud

2.46 -6.82

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.41

Max

2.68

Põhinäitajad
By Trading Economics
Sissetulek	-924K -6.3M
Müük	-180K 447K
Aktsiakasum	-0.051
Kasumimarginaal	-1,409.924
Töötajad	75
EBITDA	-724K -5M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+1415.15% upside

Turustatistika
By TradingEconomics
Turukapital	-7.3M 18M
Eelmine avamishind	9.28
Eelmine sulgemishind	2.46

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 23:08 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 23:07 UTC

Tulu

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:20 UTC

Tulu

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. apr 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. apr 2026, 23:22 UTC

Tulu

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. apr 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. apr 2026, 22:52 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:33 UTC

Tulu

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. apr 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. apr 2026, 22:05 UTC

Tulu

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 21:57 UTC

Tulu

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. apr 2026, 21:55 UTC

Tulu

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. apr 2026, 21:53 UTC

Tulu

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

1415.15% tõus

12 kuu keskmine prognoos

Keskmine 40 USD 1415.15%

Kõrge 60 USD

Madal 20 USD

Põhineb 3 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.